What is Memphasys?
Memphasys is at the forefront of reproductive biotechnology, dedicated to advancing fertility solutions. The company's primary offering is the Felix device, a sophisticated sperm separation technology already making its mark in markets such as India, Canada, and New Zealand. Beyond this flagship product, Memphasys is actively expanding its portfolio to include crucial fertility enhancers like storage media and diagnostic tools, aiming to optimize reproductive outcomes. Under the guidance of Professor John Aitken, the company is strategically positioned to lead the global fertility sector through its commitment to cutting-edge technological development.
How much funding has Memphasys raised?
Memphasys has raised a total of $3M across 1 funding round:
Other Financing Round
$3M
Other Financing Round (2021): $3M with participation from Peter Investments and Andrew Goodall
What's next for Memphasys?
The recent major strategic investment signals a pivotal phase for Memphasys, likely enabling accelerated product development and market expansion. With its existing traction in key international markets and a robust research foundation, the company is poised to further solidify its position. Future endeavors may include scaling production of the Felix device, launching new diagnostic and storage solutions, and potentially exploring further strategic partnerships to enhance its global reach and impact in the reproductive health industry.
See full Memphasys company page
